Stable Istotope Labelled Margetuximab Biosimilar – Anti-ERBB2/EGFR2/CD340 mAb – Research Grade
| Size | |
|---|---|
| Brand | |
| Product type | |
| Clonality | |
| Expression system | |
| Applications |
| Product name | Stable Istotope Labelled Margetuximab Biosimilar - Anti-ERBB2/EGFR2/CD340 mAb - Research Grade |
|---|---|
| Source | CAS 1350624-75-7 |
| Species | Chimeric |
| Expression system | Mammalian cells |
| Purity | >95% |
| Buffer | PBS buffer PH7.5 |
| Delivery condition | Blue Ice |
| Delivery Time | 3-5 days if in stock; 5-8 weeks if production needed |
| Storage condition | store at -80°C |
| Brand | ProteoGenix |
| Aliases /Synonyms | MGAH-22 |
| Reference | PX-TA1331-SIL |
| Related Products | PX-P3061 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype | IgG1-kappa |
| Clonality | Monoclonal Antibody |
| Format | Lyophilized |
| Labelling | Arginine: 13C6,15N4 ; Lysine: 13C6,15N2, >99% |
| Isotopic Enrichment | 99% |
| Stability | 1 year |
General information on Anti-ERBB2/EGFR2/CD340[Homo sapiens] (Margetuximab) Monoclonal Antibody
Margetuximab is an Fc-engineered human/mouse chimeric anti-HER2 monoclonal antibody of isotype IgG1? . Margetuximab targets the same epitope on the HER2 extracellular domain and hass the same activity as trastuzumab. However, margetuximab has a higher affinity for both CD16A variants and a weaker one to the inhibitory CD32B Fc receptor, thereby resulting in more efficient antibody-dependent cell-mediated cytotoxicity (ADCC) and higher efficacy compared to trastuzumab. Margetuximab has been marketed under the trade name Margenza.
Contact us
Send us a message from the form below
Reviews
There are no reviews yet.